Primmune Therapeutics to Present PRTX007 Phase 1 Pharmacology and Phase 2 INFLECTION-003 Study Design at the SITC 41st Annual Meeting
The issuer is solely responsible for the content of this announcement.
The issuer is solely responsible for the content of this announcement.